transforming growth factor beta receptor 2
Dernière mise à jour 18 Aug 2020
Respecte les directives éditoriales
- TéléchargerTélécharger
- Partager
- Language
- Discussion
- Version audio
- Ajouter aux sources préférées sur Google
La TGFBR2 gene provides instructions for making a protein called transforming growth factor-beta (TGF-β) receptor type 2. This receptor transmits signals from the cell surface into the cell through a process called signal transduction. Through this type of signaling, the environment outside the cell affects activities inside the cell such as stimulation of cell growth and division.
Normal function
La TGFBR2 gene provides instructions for making a protein called transforming growth factor-beta (TGF-β) receptor type 2. This receptor transmits signals from the cell surface into the cell through a process called signal transduction. Through this type of signaling, the environment outside the cell affects activities inside the cell such as stimulation of cell growth and division.
To carry out its signaling function, the TGF-β receptor type 2 spans the cell membrane, so that one end of the protein projects from the outer surface of the cell (the extracellular domain) and the other end remains inside the cell (the intracellular domain). A protein called TGF-β attaches (binds) to the extracellular domain of the TGF-β receptor type 2, which turns on (activates) the receptor and allows it to bind to another receptor on the cell surface. These three proteins form a complex, which triggers signal transduction by activating other proteins in a signaling pathway called the TGF-β pathway.
Signals transmitted by the TGF-β receptor complex trigger various responses by the cell, including the growth and division (proliferation) of cells, the maturation of cells to carry out specific functions (differentiation), cell movement (motility), and controlled cell death (apoptosis). Because TGF-β receptor type 2 helps prevent cells from growing and dividing too rapidly or in an uncontrolled way, it can suppress the formation of tumours.
Conditions referring to this gene or chromosome
Other names
HNPCC6
MFS2
RIIC
TBR-ii
TBRII
TGF-beta receptor type IIB
TGF-beta type II receptor
TGFbeta-RII
TGFR-2
TGFR2_HUMAN
transforming growth factor beta receptor II
transforming growth factor, beta receptor II (70/80kDa)
Related patient information and medicines
Patient information leaflet
Bronchodilatateurs oraux
Oral bronchodilators are medicines that are sometimes used to treat breathing problems in people with asthma and other lung-related problems such as chronic obstruct... These are beta 2 agonists (salbutamol, bambuterol and terbutaline) and methylxanthines (theophylline and aminophylline). Beta 2 agonists Work by stimulating receptors called beta 2.
Patient information leaflet
Cancer du sein
These are female hormones. Overall, about 7 in 10 breast cancers are oestrogen receptor positive. Treatment can block the oestrogen in these cancers (see below). Facteur de croissance épidermique humain (HER2) is a protéines that can affect le growth of certains cancer cells. It is found on the surface of normal breast cells. Some breast cancer cells have a very.
Patient information leaflet
Cancer de la bouche
What does mouth cancer look like. The most common mouth cancer symptoms are a sore or ulcer in... Other treatments Newer treatments are being used in research for the treatment of mouth cancer: Targeted therapy is a type of chemotherapy that only affects or targets cancer cells: The advantage it is hoped to have over conventional chemotherapy is.
Patient information leaflet
Bêta-bloquants
Beta-blockers are medicines that are used to treat a variety of conditions. Their full correct name is beta-adrenoceptor blocking medicines (ou beta-adrenergic blocking agents), but they are commonly just called beta-blockers. How do beta-blockers work. Beta-blockers work by blocking the transmission of certain nerve impulses. The ends of some.
Patient information leaflet
Cancer de la gorge
Throat cancer symptoms A hoarse voice is often the first symptom because most cancers of the larynx first start on, or close by, a vocal cord. The problem is a hoarse voice is a common symptom of a viral infection of the larynx ( laryngitis ). It is a type of monoclonal antibody which means that it c... These proteins are epidermal growth factor.
Patient information leaflet
Régime 5:2
La Régime 5:2 is a calorie-restricted diet that involves eating 'normally' for five days out of seven and then 'fasting' on the other two days out of seven. The proposed health effects of the 5:2 diet include weight loss, improvement in life expectancy, protection against certain cancers and protection against dementia. The theory is that the.
Lectures complémentaires et références
- transforming growth factor beta receptor 2; MedlinePlus, National Library of Medicine.
- Biswas S, Trobridge P, Romero-Gallo J, Billheimer D, Myeroff LL, Willson JK, Markowitz SD, Grady WM. Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells. Genes Chromosomes Cancer. 2008 Feb;47(2):95-106. doi: 10.1002/gcc.20511.
- Frederic MY, Hamroun D, Faivre L, Boileau C, Jondeau G, Claustres M, Beroud C, Collod-Beroud G. A new locus-specific database (LSDB) for mutations in the TGFBR2 gene: UMD-TGFBR2. Hum Mutat. 2008 Jan;29(1):33-8. doi: 10.1002/humu.20602.
- Jondeau G, Boileau C. Genetics of thoracic aortic aneurysms. Curr Atheroscler Rep. 2012 Jun;14(3):219-26. doi: 10.1007/s11883-012-0241-4.
- Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, Meyers J, Leitch CC, Katsanis N, Sharifi N, Xu FL, Myers LA, Spevak PJ, Cameron DE, De Backer J, Hellemans J, Chen Y, Davis EC, Webb CL, Kress W, Coucke P, Rifkin DB, De Paepe AM, Dietz HC. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005 Mar;37(3):275-81. doi: 10.1038/ng1511. Epub 2005 Jan 30.
- Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu H, De Backer JF, Oswald GL, Symoens S, Manouvrier S, Roberts AE, Faravelli F, Greco MA, Pyeritz RE, Milewicz DM, Coucke PJ, Cameron DE, Braverman AC, Byers PH, De Paepe AM, Dietz HC. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med. 2006 Aug 24;355(8):788-98. doi: 10.1056/NEJMoa055695.
- Pannu H, Fadulu VT, Chang J, Lafont A, Hasham SN, Sparks E, Giampietro PF, Zaleski C, Estrera AL, Safi HJ, Shete S, Willing MC, Raman CS, Milewicz DM. Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation. 2005 Jul 26;112(4):513-20. doi: 10.1161/CIRCULATIONAHA.105.537340. Epub 2005 Jul 18.
- Pezzini A, Del Zotto E, Giossi A, Volonghi I, Costa P, Padovani A. Transforming growth factor beta signaling perturbation in the Loeys-Dietz syndrome. Curr Med Chem. 2012;19(3):454-60. doi: 10.2174/092986712803414286.
- Van Hemelrijk C, Renard M, Loeys B. The Loeys-Dietz syndrome: an update for the clinician. Curr Opin Cardiol. 2010 Nov;25(6):546-51. doi: 10.1097/HCO.0b013e32833f0220.
Participez à la conversation
Partagez vos pensées ou expériences avec les autres dans notre communautés de patients.
Demandez, partagez, connectez-vous.
Parcourez les discussions, posez des questions et partagez vos expériences sur des centaines de sujets de santé.
Inscrivez-vous à la newsletter Patient
Votre dose hebdomadaire de conseils de santé clairs et fiables - rédigés pour vous aider à vous sentir informé, confiant et maître de la situation.
En vous abonnant, vous acceptez notre Politique de confidentialité. Vous pouvez vous désabonner à tout moment. Nous ne vendons jamais vos données.